Clayman G L, Liu F J, Savage H E, Taylor D L, Lavedan P, Buchsbaum R M, Pellegrino C, Trujillo J M, Young G, Schantz S P
Department of Head and Neck Surgery, University of Texas M.D. Anderson Cancer Center, Houston.
Arch Otolaryngol Head Neck Surg. 1992 Jan;118(1):41-8. doi: 10.1001/archotol.1992.01880010045014.
Circulating acute-phase proteins may mediate adverse reactions in patients receiving biologic response modifiers, including inhibition of immune responsiveness and clinical toxic effects. Nine patients with unresectable head and neck squamous cell carcinoma were prospectively examined for levels of acute-phase proteins during interleukin 2/interferon alfa immunotherapy and for clinical toxic effects. Simultaneous determination of the in vitro immunomodulatory capacity of autologous serum on the induction of lymphokine-activated killer cells was assessed in 4-hour chromium release assays. Of the seven acute-phase proteins analyzed, haptoglobin and C-reactive protein levels were elevated before therapy was started. Toxic events leading to cessation of interleukin 2/interferon alfa therapy had a high correlation with elevated C-reactive protein and lowered C3 component of complement levels. No relationship was noted between serum levels of acute-phase proteins and induction inhibition of lymphokine-activated killer cell cytotoxicity. The role of C-reactive protein and complement degradation products in mediating interleukin 2/interferon alfa toxicity requires further investigation.
循环中的急性期蛋白可能介导接受生物反应调节剂治疗的患者的不良反应，包括免疫反应性抑制和临床毒性作用。对9例不可切除的头颈部鳞状细胞癌患者进行前瞻性研究，检测其在白细胞介素2/α干扰素免疫治疗期间的急性期蛋白水平及临床毒性作用。在4小时铬释放试验中评估自体血清对淋巴因子激活的杀伤细胞诱导的体外免疫调节能力。在所分析的7种急性期蛋白中，触珠蛋白和C反应蛋白水平在治疗开始前升高。导致白细胞介素2/α干扰素治疗中断的毒性事件与C反应蛋白升高和补体C3成分水平降低高度相关。急性期蛋白血清水平与淋巴因子激活的杀伤细胞细胞毒性诱导抑制之间未发现相关性。C反应蛋白和补体降解产物在介导白细胞介素2/α干扰素毒性中的作用需要进一步研究。
